Petmed Express, Inc. · NASDAQ:PETS
Petmed Express — Q1 2024 Earnings Presentation
11 slides from Petmed Express's earnings presentation, Jul 31, 2023
Slide 1: 1Q24 Earnings Call
NASDAQ: PETS 1Q24 Earnings Call July 2023
Slide 2: Safe Harbor & Non-GAAP Measures
Safe Harbor & Non-GAAP Measures This Presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended
Slide 3: Your Trusted Pet Health Expert
Your Trusted Pet Health Expert VISION Every pet deserves to live a long, happy, healthy life MISSION PetMeds aims to be the most trusted pet health expert by providing incredible care and services that are affordable to the broadest group of pet parents. 3
Slide 4: Integrating PetCareRx
Integrating PetCareRx Additional products, higher LTV, expanded distribution capabilities • Coordinate demand generation • Expand addressable market • Expand distribution and shipping • Increase product availability • Increased buying power • Higher LTV and wallet share Medication Nutrition 4
Slide 5: Quarterly Results Overview
Quarterly Results Overview Founded in 1996, PetMeds is “Your Trusted Pet Health Expert” providing fast, easy and helpful service to over 11 million customers across the U.S. NASDAQ: PETS Share Price1 $14.19 Market Cap1 $306.6M Fiscal First Quarter Highlights FY 2023 Revenue $256.9M • $78.2 million i
Slide 6: Total Wellness: "From Nose to Tail"
Total Wellness: “From Nose to Tail” Additional growth, transaction and partnership opportunities Product Expansion Telemedicine Insurance Medication Care Wellness Nutrition 6
Slide 7: Financial Overview
FINANCIAL OVERVIEW
Slide 8: Select Financials
Select Financials 3 Months Ended June 30, $ in Millions 2023 2022 Sales $78.2 $70.2 Gross Profit 22.5 19.9 Operating Expenses (24.7) (16.4) Adj. EBITDA1 $3.3 $6.3 Net Income ($0.9) $2.8 Dividend $0.30 $0.30 Cash & Cash Equivalents $61.5 $105.4 Year-over-year revenue and gross margin growth with re-a
Slide 9: Capital Allocation Strategy
Capital Allocation Strategy Organic Inorganic Return to Growth Growth Shareholders Working Alliances & Share Capex Acquisitions Dividends Capital Partnerships Repurchases 9
Slide 10: Investment Highlights
Investment Highlights Increasing revenue is key to transition to a growth- focused business Strategic plan: integrate PetCareRx, expand new customers, provide more products and deliver unique and differentiated services Strong market demand for pet medication in pet category resilient to economic he
Slide 11: www.petmeds.com
Company Christine Chambers Chief Financial Officer 561-526-4444 Investor Relations Brian M. Prenoveau, CFA MZ Group 561-489-5315 investor@petmeds.com www.petmeds.com